Literature DB >> 22722620

Level of evidence reviews: three years of progress.

Eric J Ashman, Gary S Gronseth.   

Abstract

Mesh：

Year:  2012        PMID： 22722620     DOI： 10.1212/WNL.0b013e31825dce83

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  8 in total

1.  An update on the management of chronic inflammatory demyelinating polyneuropathy.

Authors:  Kenneth C Gorson
Journal:  Ther Adv Neurol Disord       Date:  2012-11       Impact factor: 6.570

Review 2.  Pharmacologic management of chronic neuropathic pain: Review of the Canadian Pain Society consensus statement.

Authors:  Alex Mu; Erica Weinberg; Dwight E Moulin; Hance Clarke
Journal:  Can Fam Physician       Date:  2017-11       Impact factor: 3.275

Review 3.  Epidemiological evidence that physical activity is not a risk factor for ALS.

Authors:  Bello Hamidou; Philippe Couratier; Cyril Besançon; Marie Nicol; Pierre Marie Preux; Benoit Marin
Journal:  Eur J Epidemiol       Date:  2014-07-02       Impact factor: 8.082

4.  Automated detection of cortical dysplasia type II in MRI-negative epilepsy.

Authors:  Seok-Jun Hong; Hosung Kim; Dewi Schrader; Neda Bernasconi; Boris C Bernhardt; Andrea Bernasconi
Journal:  Neurology       Date:  2014-06-04       Impact factor: 9.910

5.  Multicenter Validation of a Deep Learning Detection Algorithm for Focal Cortical Dysplasia.

Authors:  Ravnoor Singh Gill; Hyo-Min Lee; Benoit Caldairou; Seok-Jun Hong; Carmen Barba; Francesco Deleo; Ludovico D'Incerti; Vanessa Cristina Mendes Coelho; Matteo Lenge; Mira Semmelroch; Dewi Victoria Schrader; Fabrice Bartolomei; Maxime Guye; Andreas Schulze-Bonhage; Horst Urbach; Kyoo Ho Cho; Fernando Cendes; Renzo Guerrini; Graeme Jackson; R Edward Hogan; Neda Bernasconi; Andrea Bernasconi
Journal:  Neurology       Date:  2021-09-14       Impact factor: 9.910

6.  Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society.

Authors:  Dwight Moulin; Aline Boulanger; A J Clark; Hance Clarke; Thuan Dao; G A Finley; Andrea Furlan; Ian Gilron; Allan Gordon; Patricia K Morley-Forster; Barry J Sessle; Pamela Squire; Jennifer Stinson; Paul Taenzer; Ana Velly; Mark A Ware; Erica L Weinberg; Owen D Williamson
Journal:  Pain Res Manag       Date:  2014 Nov-Dec       Impact factor: 3.037

Review 7.  Vaccination in Multiple Sclerosis: Friend or Foe?

Authors:  Tobias Zrzavy; Herwig Kollaritsch; Paulus S Rommer; Nina Boxberger; Micha Loebermann; Isabella Wimmer; Alexander Winkelmann; Uwe K Zettl
Journal:  Front Immunol       Date:  2019-08-07       Impact factor: 7.561

8.  Botulinum neurotoxin treatment in jerky and tremulous functional movement disorders: a double-blind, randomised placebo-controlled trial with an open-label extension.

Authors:  Yasmine Emma Maria Dreissen; Joke M Dijk; Jeannette M Gelauff; Evelien Zoons; Daniël van Poppelen; Maria Fiorella Contarino; Rodi Zutt; Bart Post; Alexander G Munts; Johannes D Speelman; Danielle C Cath; Rob J de Haan; Johannes Htm Koelman; Marina A J Tijssen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2019-06-20       Impact factor: 10.154
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.